{"id":2165,"date":"2010-11-23T10:49:10","date_gmt":"2010-11-23T15:49:10","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=2165"},"modified":"2010-11-23T10:49:10","modified_gmt":"2010-11-23T15:49:10","slug":"u-s-europe-patents-issued-for-rnai-drug-delivery","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=2165","title":{"rendered":"U.S., Europe Patents Issued for RNAi Drug Delivery"},"content":{"rendered":"<figure id=\"attachment_472\" aria-describedby=\"caption-attachment-472\" style=\"width: 200px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/08\/DNAFragment_WMC_200.png\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-472\" title=\"DNAFragment_WMC_200\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/08\/DNAFragment_WMC_200.png\" alt=\"DNA fragment (Wikimedia Commons)\" width=\"200\" height=\"221\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/08\/DNAFragment_WMC_200.png 200w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/08\/DNAFragment_WMC_200-135x150.png 135w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/a><figcaption id=\"caption-attachment-472\" class=\"wp-caption-text\">(Wikimedia Commons)<\/figcaption><\/figure>\n<p>Tekmira Pharmaceuticals Corp. in Vancouver, Canada, a developer of RNA interference (RNAi) therapeutics, says that the United States Patent and Trademark Office (USPTO) and European Patent Office (EPO) have<a href=\"http:\/\/www.tekmirapharm.com\/News_and_Events\/News_Releases\/Tekmira11221002.aspx\"> issued patents <\/a>covering elements of Tekmira&#8217;s lipid nanoparticle technology for delivering nucleic acid therapeutics, including small interfering RNA (siRNA).<\/p>\n<p>RNAi therapeutics have the <a href=\"http:\/\/www.nature.com\/nbt\/journal\/v23\/n4\/abs\/nbt1081.html\">potential to treat<\/a> a broad number of human diseases by &#8220;silencing&#8221; disease causing genes. Tekmira says RNAi therapeutics, such as siRNAs, require delivery technology, such as lipid nanoparticles, to be systematically effective.<\/p>\n<p>The EPO has granted claims (No. 1 519 714 B1) covering Tekmira\u2019s manufacturing process and apparatus for the production of lipid nanoparticles, a process reviewed by multiple international regulatory agencies and used in several ongoing clinical trials.<\/p>\n<p>The USPTO has granted claims (No. 7,807,815) covering the identification and modification of siRNA sequence motifs responsible for immune stimulation.\u00a0 Tekmira says this case is the first in a series of patent filings covering methods of mitigating siRNA immune stimulation through chemical modification.\u00a0 These claims flow from Tekmira&#8217;s research on the sequence-dependent stimulation of the innate immune response by nucleic acids, including siRNA.<\/p>\n<p>Tekmira provides its technology through manufacturing services to pharmaceutical partners, including Alnylam Pharmaceuticals, Bristol-Myers Squibb, Takeda, the United States government&#8217;s Transformational Medical Technologies program.<\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tekmira Pharmaceuticals Corp. in Vancouver, Canada, a developer of RNA interference (RNAi) therapeutics, says that the United States Patent and Trademark Office (USPTO) and European Patent Office (EPO) have issued patents covering elements of Tekmira&#8217;s lipid nanoparticle technology for delivering nucleic acid therapeutics, including small interfering RNA (siRNA). RNAi therapeutics have the potential to treat [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[21,45,55,64,29,7],"class_list":["post-2165","post","type-post","status-publish","format-standard","hentry","category-i-p","tag-biotech","tag-europe","tag-genomics","tag-life-sciences","tag-patent","tag-uspto"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2165"}],"version-history":[{"count":4,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2165\/revisions"}],"predecessor-version":[{"id":2169,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/2165\/revisions\/2169"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}